aTyr Pharma, Inc. (LIFE): Price and Financial Metrics

aTyr Pharma, Inc. (LIFE): $1.90

0.05 (+2.70%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

F

Add LIFE to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#305 of 356

in industry

LIFE Price/Volume Stats

Current price $1.90 52-week high $2.45
Prev. close $1.85 52-week low $1.08
Day low $1.82 Volume 269,400
Day high $1.95 Avg. volume 514,103
50-day MA $1.76 Dividend yield N/A
200-day MA $1.59 Market Cap 131.12M

LIFE Stock Price Chart Interactive Chart >


aTyr Pharma, Inc. (LIFE) Company Bio


aTyr Pharma, Inc. is a biotherapeutics company, engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology. aTyr research and development focuses on the extracellular functionality and signaling pathways of tRNA synthetases. Over the last ten years, the company has developed an international portfolio of intellectual property, including 20 human tRNA synthetases and over 300 protein compositions patented. Sanjay S. Shukla, M.D., M.S. has served as our President and Chief Executive Officer and as a board member since November 2017. aTyr’s headquarters is located in San Diego, California and the company employs 42 people.


LIFE Latest News Stream


Event/Time News Detail
Loading, please wait...

LIFE Latest Social Stream


Loading social stream, please wait...

View Full LIFE Social Stream

LIFE Price Returns

1-mo N/A
3-mo N/A
6-mo 5.56%
1-year 62.39%
3-year -76.25%
5-year -54.87%
YTD 34.75%
2023 -35.62%
2022 -70.68%
2021 92.53%
2020 -6.95%
2019 -39.95%

Continue Researching LIFE

Want to see what other sources are saying about aTYR PHARMA INC's financials and stock price? Try the links below:

aTYR PHARMA INC (LIFE) Stock Price | Nasdaq
aTYR PHARMA INC (LIFE) Stock Quote, History and News - Yahoo Finance
aTYR PHARMA INC (LIFE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!